Education
About Us
Working with TipRanks
Follow Us
ALISON MOORE Insider Profile
4 Followers
ALISON MOORE, CTO at Allogene Therapeutics, holds 250.51K shares in Codexis (Ticker: CDXS), holds 672.73K shares in Allogene Therapeutics (Ticker: ALLO), holds ― shares in Artiva Biotherapeutics, Inc. (Ticker: ARTV). Most recently, ALISON MOORE Sold ― shares of Codexis on Feb 09, 2026 for an estimated value of $4.97K.
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+33.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that ALISON MOORE holds in companies
Most Profitable Insider Trade
The most profitable trade made by ALISON MOORE
ALISON MOORE's Trading History
Allogene Therapeutics
Mar 24, 2023
CTO
Uninformative Buy
―
$1.70M
Codexis
Feb 09, 2026
President & CEO, Director
Informative Sell
4.97K
$280.57K
Artiva Biotherapeutics, Inc.
―
Director
―
―
List of latest transactions for each holding click on a transaction to see ALISON MOORE's performance on stock
You May Also Like
ALISON MOORE insider profile FAQ
What is the percentage of profitable transactions made by ALISON MOORE?
The percentage of profitable transactions made by ALISON MOORE is 100%.
What is the average return per transaction made by ALISON MOORE?
The average return per transaction made by ALISON MOORE is 33.20%.
What stocks does ALISON MOORE hold?
ALISON MOORE holds: ALLO, CDXS, ARTV stocks.
What was ALISON MOORE’s latest transaction?
ALISON MOORE latest transaction was an Informative Sell of $4.97K.
What was ALISON MOORE's most profitable transaction?
ALISON MOORE’s most profitable transaction was an Informative Sell of CDXS stock on October 15, 2025. The return on the trade was 57.20%.
What is ALISON MOORE's role in Allogene Therapeutics?
ALISON MOORE's role in Allogene Therapeutics is CTO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.